Patient Access Services (PAS) – HEOR, RWE, PRMA and Scientific Communications Consulting

In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever-increasing costs and abating healthcare budgets, payers (both national and local) have a significant and growing influence on a product's commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product's success.

PAS services outsourcing is an attractive strategy when specialised skills are required for varying study types and India has always been considered as a preferred destination due to cost effectiveness, better time management and utmost quality of deliverables.

MarksMan Healthcare Solutions (ISO 27001:2013), a non-profit division of path finders charitable trust, is an International knowledge-based Patient Access Services (PAS) and Scientific Communications consulting firm based in Navi Mumbai, India. We provide services pertaining to “Health Economics and Outcomes Research (HEOR), Real World Evidence (RWE), Pricing Reimbursement and Market Access (PRMA) and Scientific Communications" to maximize the opportunities of pharmaceutical products during a decision making process.

The foundation of MarksMan services is to provide clinical and economic evidence that aims to support our client's product positioning, Health Technology Assessment (HTA) and reimbursement. Our expertise lies in developing product value evidence such as clinical efficacy, real-world data, patient quality of life reports, and opportunity cost of various treatment mixes, budget impact, and cost-effectiveness models.

Insights given by MarksMan can provide provable evidence for payers and can help pharmaceutical companies to overcome the evolving market access challenges. This adds lot of value both to the industry and the patients, who ultimately experience better health outcomes.

MEET THE TEAM


LATEST FROM BLOG


30May 2017

The “Internet of things” (IoT) is becoming an increasingly growing topic of conversation both in the workplace and outside of it. It’s a concept that not only has the potential to impact how we live but also how we work. The internet of things (IoT) is the internetworking of physical devices, vehicles, buildings and other items embedded with electronics, software, sensors, actuators, […]


Latest Publications

Updated list of scientific publications that our writers have successfully achieved post getting associated with us (MarksMan and Geronimo) since year 2012 

  1. 1
    Efficacy and Safety of Canagliflozin Among Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

    Kaur K, Likar N, Dang A, Kaur G. Efficacy and Safety of Canagliflozin Among Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Indian J Endocr Metab 2015;19:705-21

  2. 2
    Phytomedicine in the Treatment of Cancer: A Health Technology Assessment.

    Chaudhary T, Chahar A, Sharma JK, Kaur K, Dang A. Phytomedicine in the Treatment of Cancer: A Health Technology Assessment. J Clin Diagn Res. 2015 Dec;9(12):XC04-XC09

  3. 3
    A Post-marketing Study Evaluating the Lipid Altering Efficacy and Safety of Approved Dose Ranges of Rosuvastatin in Indian Hyperlipidemia Patients in Routine Clinical Practice (ROSUVEES).

    Shah CP, Kumbla DK, Moorthy A, Murthy S, Aneja P, Gotur J, Gupta A, Abhi R, Bansal R, Sonawala S, Balani AG, Kedarnathan R, Soni P, Chinnaiyann P. A post-marketing study evaluating the lipid-altering efficacy and safety of approved dose ranges of rosuvastatin in Indian hyperlipidemia patients in routine clinical practice (ROSUVEES). JICC 2015; 5(4): 282-290 

  4. 4
    Reduced Risk of Parkinson’s Disease in Users of Calcium Channel Blockers: A Meta-analysis.

    K Gudala, R Kanukula, D Bansal. Reduced Risk of Parkinson’s Disease in Users of Calcium Channel Blockers: A Meta-analysis. International Journal of chronic diseases. Volume 2015 (2015), Article ID 697404, 7 

  5. 5
    Effectiveness and Safety of Fixed Dose Combination of Acarbose/metformin in Indian Type 2 Diabetes Patients: Results from Observational GLOBE Study.

    Saboo B, Reddy GC, Juneja S, Kedia AK, Manjrekar P, Rathod R. Effectiveness and Safety of Fixed Dose Combination of Acarbose/metformin in Indian Type 2 Diabetes Patients: Results from Observational GLOBE Study. Indian J Endocr Metab 2015;19:129-35

More